within Pharmacolibrary.Drugs.ATC.L;

model L01AC01_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 31 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,
    adminCount     = 1,
    Vd             = 0.00156,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Thiotepa is an alkylating agent of the ethyleneimine type, used primarily as an antineoplastic chemotherapy drug. It has been indicated for use in the treatment of various cancers including breast cancer, ovarian cancer, and bladder cancer. Thiotepa is approved for use as a conditioning treatment prior to hematopoietic stem cell transplantation and for high-dose chemotherapy settings.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for pediatric patients undergoing stem cell transplantation using intravenous thiotepa.</p><h4>References</h4><ol><li><p>Ackland, SP, et al., &amp; Bitran, JD (1988). Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide. <i>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</i> 6(7) 1192–1196. DOI:<a href=&quot;https://doi.org/10.1200/JCO.1988.6.7.1192&quot;>10.1200/JCO.1988.6.7.1192</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3134519/&quot;>https://pubmed.ncbi.nlm.nih.gov/3134519</a></p></li><li><p>Strong, JM, et al., &amp; Poplack, DG (1986). Pharmacokinetics of intraventricular and intravenous N,N&#x27;,N&#x27;&#x27;-triethylenethiophosphoramide (thiotepa) in rhesus monkeys and humans. <i>Cancer research</i> 46(12 Pt 1) 6101–6104. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3096555/&quot;>https://pubmed.ncbi.nlm.nih.gov/3096555</a></p></li><li><p>Ekhart, C, et al., &amp; Huitema, AD (2009). Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen. <i>Therapeutic drug monitoring</i> 31(1) 95–103. DOI:<a href=&quot;https://doi.org/10.1097/FTD.0b013e318194e484&quot;>10.1097/FTD.0b013e318194e484</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19155964/&quot;>https://pubmed.ncbi.nlm.nih.gov/19155964</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01AC01_1;
